{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T17:27:20Z","timestamp":1758216440162,"version":"3.44.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Conditioning with high-dose melphalan (MEL) followed by autologous stem cell transplantation (ASCT) is the standard treatment for multiple myeloma (MM). The optimal regimen to prevent chemotherapy-induced nausea and vomiting (CINV) is unclear. We aimed to retrospectively evaluate the antiemetic effect and safety of a four-drug intensive regimen including olanzapine (OLA) on CINV in MM patients receiving MEL\/ASCT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>MEL (200\u00a0mg\/m<jats:sup>2<\/jats:sup>) was administered on day 1, followed by ASCT on day 3. Patients were classified into the standard group (palonosetron and dexamethasone on day 1, and aprepitant on day 1\u20133), and the intensive antiemetic regimen (IAR) group (palonosetron on day 1, dexamethasone on day 1\u20132, and aprepitant, and OLA on day 1\u20135). The primary endpoint was defined as no vomiting and no rescue medications (complete response) in the delayed phase (day 2\u20135).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>There were no significant differences in baseline characteristics between the OLA (n\u2009=\u200968) and standard (n\u2009=\u200954) groups. The complete response rate in the IAR group was significantly higher in the delayed phase (52.9% vs. 31.4%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Multivariate analysis revealed that the IAR was associated with the complete response rate (OR, 2.34; 95% CI, 1.09\u20135.00; <jats:italic>p<\/jats:italic>\u2009=\u20090.028). The incidence of nausea (grade 3) in the delayed phase was lower in the IAR group (44.1% vs. 75.9%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The four-drug intensive regimen including OLA may improve the antiemetic effect on delayed CINV while also ensuring safety in MM patients undergoing MEL\/ASCT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00520-025-09839-2","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T03:13:59Z","timestamp":1754882039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of intensive antiemetic therapy including olanzapine in multiple myeloma patients treated with high-dose melphalan with autologous stem cell transplantation"],"prefix":"10.1007","volume":"33","author":[{"given":"Junpei","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Tatsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yoshimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Shiko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itsuko","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"14","key":"9839_CR1","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M et al (2017) Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 376(14):1311\u20131320. https:\/\/doi.org\/10.1056\/NEJMoa1611750","journal-title":"N Engl J Med"},{"issue":"2","key":"9839_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS et al (2022) Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 387(2):132\u2013147. https:\/\/doi.org\/10.1056\/NEJMoa2204925","journal-title":"N Engl J Med"},{"issue":"4","key":"9839_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1200\/JCO.1994.12.4.759","volume":"12","author":"D Cunningham","year":"1994","unstructured":"Cunningham D, Paz-Ares L, Milan S, Powles R, Nicolson M, Hickish T et al (1994Apr) High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 12(4):759\u2013763. https:\/\/doi.org\/10.1200\/JCO.1994.12.4.759","journal-title":"J Clin Oncol"},{"issue":"25","key":"9839_CR4","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1056\/NEJMct0805626","volume":"360","author":"JL Harousseau","year":"2009","unstructured":"Harousseau JL, Moreau P (2009) Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 360(25):2645\u20132654. https:\/\/doi.org\/10.1056\/NEJMct0805626","journal-title":"N Engl J Med"},{"key":"9839_CR5","unstructured":"Berger MJ, Agarwal R, Anand S, Bagegni NA, Barbour S, \u03a3 B, et al. NCCN Guidelines Version 2.2023 Antiemesis Continue. 2023. Available from: https:\/\/www.nccn."},{"issue":"30","key":"9839_CR6","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1200\/JCO.2013.55.0095","volume":"32","author":"T Schmitt","year":"2014","unstructured":"Schmitt T, Goldschmidt H, Neben K, Freiberger A, H\u00fcsing J, Gronkowski M et al (2014) Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 32(30):3413\u20133420. https:\/\/doi.org\/10.1200\/JCO.2013.55.0095","journal-title":"J Clin Oncol"},{"issue":"6","key":"9839_CR7","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/bmt.2010.205","volume":"46","author":"K Jordan","year":"2011","unstructured":"Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J et al (2011) The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant 46(6):784\u2013789. https:\/\/doi.org\/10.1038\/bmt.2010.205","journal-title":"Bone Marrow Transplant"},{"key":"9839_CR8","doi-asserted-by":"publisher","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL, et al. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open. 2024 Feb 1;9(2). https:\/\/doi.org\/10.1016\/j.esmoop.2023.102195","DOI":"10.1016\/j.esmoop.2023.102195"},{"key":"9839_CR9","doi-asserted-by":"publisher","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Rebecca, et al. Antiemetics: ASCO Guideline Update. Vol. 38, J Clin Oncol. 2020. https:\/\/doi.org\/10.1200\/JCO.20.01296","DOI":"10.1200\/JCO.20.01296"},{"key":"9839_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00520-018-4594-2","volume":"27","author":"A Tendas","year":"2019","unstructured":"Tendas A, Marchesi F, Mengarelli A, Annibali O, Tomarchio V, Saltarelli D et al (2019) Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions. Support Care Cancer 27:793\u2013803. https:\/\/doi.org\/10.1007\/s00520-018-4594-2","journal-title":"Support Care Cancer"},{"issue":"5","key":"9839_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9(5):188\u2013195. https:\/\/doi.org\/10.1016\/j.suponc.2011.05.002","journal-title":"J Support Oncol"},{"issue":"2","key":"9839_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(2):242\u2013249. https:\/\/doi.org\/10.1016\/S1470-2045(19)30678-3","journal-title":"Lancet Oncol"},{"issue":"1","key":"9839_CR13","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.bbmt.2018.06.005","volume":"24","author":"AB Clemmons","year":"2018","unstructured":"Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D (2018) Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O trial. Biol Blood Marrow Transplant 24(1):2065\u20132071. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"9839_CR14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.clml.2017.06.012","volume":"17","author":"S Trifilio","year":"2017","unstructured":"Trifilio S, Welles C, Seeger K, Mehta S, Fishman MA, McGowan K et al (2017) Olanzapine reduces chemotherapy-induced nausea and vomiting compared with aprepitant in myeloma patients receiving high-dose melphalan before stem cell transplantation: a retrospective study. Clin Lymphoma Myeloma Leuk 17(9):584\u2013589. https:\/\/doi.org\/10.1016\/j.clml.2017.06.012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"9839_CR15","doi-asserted-by":"publisher","unstructured":"Hata A, Okamoto I, Inui ; Naoki, Okada M, Morise M, Akiyoshi K, et al. Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE. J Clin Oncol. 2021;40:180\u20138. https:\/\/doi.org\/10.1200\/JCO.21.01315","DOI":"10.1200\/JCO.21.01315"},{"issue":"4","key":"9839_CR16","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s12185-016-2152-6","volume":"105","author":"A Isoda","year":"2017","unstructured":"Isoda A, Saito R, Komatsu F, Negishi Y, Oosawa N, Ishikawa T et al (2017) Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: a phase II study. Int J Hematol 105:478\u2013484. https:\/\/doi.org\/10.1007\/s12185-016-2152-6","journal-title":"Int J Hematol"},{"key":"9839_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-024-02535-x","author":"H Iihara","year":"2024","unstructured":"Iihara H, Abe M, Wada M, Iino K, Akechi T, Imamura CK et al (2024) 2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis. Int J Clin Oncol. https:\/\/doi.org\/10.1007\/s10147-024-02535-x","journal-title":"Int J Clin Oncol"},{"key":"9839_CR18","doi-asserted-by":"publisher","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Intergroupe Fran\u00e7ais du My\u00e9lome et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335(2):91\u201397. https:\/\/doi.org\/10.1056\/NEJM199607113350204","DOI":"10.1056\/NEJM199607113350204"},{"issue":"19","key":"9839_CR19","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348(19):1875\u20131883. https:\/\/doi.org\/10.1056\/NEJMoa022340","journal-title":"N Engl J Med"},{"issue":"6","key":"9839_CR20","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/bmt.2014.56","volume":"49","author":"SR Parmar","year":"2014","unstructured":"Parmar SR, Bookout R, Shapiro JF, Tombleson R, Perkins J, Kim J et al (2014) Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma. Bone Marrow Transplant 49(6):761\u2013766. https:\/\/doi.org\/10.1038\/bmt.2014.56","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"9839_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/bmt.2013.152","volume":"49","author":"Z Shu","year":"2014","unstructured":"Shu Z, Heimfeld S, Gao D (2014) Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion. Bone Marrow Transplant 49(4):469\u2013476. https:\/\/doi.org\/10.1038\/bmt.2013.152","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"9839_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","volume":"23","author":"T Yanai","year":"2018","unstructured":"Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K et al (2018) A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol 23(2):382\u2013388. https:\/\/doi.org\/10.1007\/s10147-017-1200-4","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"9839_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.suponc.2011.10.007","volume":"10","author":"L Bourdeanu","year":"2012","unstructured":"Bourdeanu L, Frankel P, Yu W, Hendrix G, Pal S, Badr L et al (2012) Chemotherapy-induced nausea and vomiting in Asian women with breast cancer receiving anthracycline-based adjuvant chemotherapy. J Support Oncol 10(4):149\u2013154. https:\/\/doi.org\/10.1016\/j.suponc.2011.10.007","journal-title":"J Support Oncol"},{"issue":"1","key":"9839_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00280-008-0713-y","volume":"63","author":"S Nakade","year":"2008","unstructured":"Nakade S, Ohno T, Kitagawa J, Hashimoto Y, Katayama M, Awata H et al (2008) Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol 63(1):75\u201383. https:\/\/doi.org\/10.1007\/s00280-008-0713-y","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"9839_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0009-9236(03)00066-3","volume":"74","author":"JB McCrea","year":"2003","unstructured":"McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL et al (2003Jul) Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 74(1):17\u201324. https:\/\/doi.org\/10.1016\/S0009-9236(03)00066-3","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"9839_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/0091270005283467","volume":"46","author":"AK Majumdar","year":"2006","unstructured":"Majumdar AK, Howard L, Goldberg MR, Hickey L, Constanzer M, Rothenberg PL et al (2006) Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol 46(3):291\u2013300. https:\/\/doi.org\/10.1177\/0091270005283467","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"9839_CR27","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/s0885-3924(03)00143-x","volume":"25","author":"M Srivastava","year":"2003","unstructured":"Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R (2003) Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage 25(6):578\u2013582. https:\/\/doi.org\/10.1016\/s0885-3924(03)00143-x","journal-title":"J Pain Symptom Manage"},{"issue":"10","key":"9839_CR28","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1001\/jama.298.10.1196","volume":"298","author":"GJ Wood","year":"2007","unstructured":"Wood GJ, Shega JW, Lynch B, Von Roenn JH (2007) Management of intractable nausea and vomiting in patients at the end of life: \u201cI was feeling nauseous all of the time \u2026 nothing was working.\u201d JAMA 298(10):1196\u20131207. https:\/\/doi.org\/10.1001\/jama.298.10.1196","journal-title":"JAMA"},{"issue":"3","key":"9839_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","volume":"37","author":"JT Callaghan","year":"1999","unstructured":"Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM (1999) Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37(3):177\u2013193. https:\/\/doi.org\/10.2165\/00003088-199937030-00001","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"9839_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/oxfordjournals.annonc.a057871","volume":"2","author":"M Tonato","year":"1991","unstructured":"Tonato M, Roila F, Del Favero A (1991) Methodology of antiemetic trials: a review. Ann Oncol 2(2):107\u2013114. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a057871","journal-title":"Ann Oncol"},{"issue":"6","key":"9839_CR31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/cas.12146","volume":"104","author":"I Sekine","year":"2013","unstructured":"Sekine I, Segawa Y, Kubota K, Saeki T (2013) Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci 104(6):711\u2013717. https:\/\/doi.org\/10.1111\/cas.12146","journal-title":"Cancer Sci"},{"issue":"5","key":"9839_CR32","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/0277-5379(89)90138-7","volume":"25","author":"A Osterborg","year":"1989","unstructured":"Osterborg A, Ehrsson H, Eksborg S, Wallin I, Mellstedt H (1989) Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients. Eur J Cancer Clin Oncol 25(5):899\u2013903. https:\/\/doi.org\/10.1016\/0277-5379(89)90138-7","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"6A","key":"9839_CR33","first-page":"2379","volume":"14","author":"MF Kergueris","year":"1994","unstructured":"Kergueris MF, Milpied N, Moreau P, Harousseau JL, Larousse C (1994) Pharmacokinetics of high-dose melphalan in adults: influence of renal function. Anticancer Res 14(6A):2379\u20132382","journal-title":"Anticancer Res"},{"issue":"5","key":"9839_CR34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.14740\/jh1148","volume":"12","author":"SG Ursu","year":"2023","unstructured":"Ursu SG, Maples S, Williams KJ, Patrus G, Samhouri Y, Fazal S et al (2023) The impact of renal impairment in multiple myeloma patients undergoing autologous stem cell transplantation with melphalan conditioning. J Hematol 12(5):201\u2013207. https:\/\/doi.org\/10.14740\/jh1148","journal-title":"J Hematol"},{"issue":"13","key":"9839_CR35","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","volume":"34","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E et al (2016May 1) International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 34(13):1544\u20131557. https:\/\/doi.org\/10.1200\/JCO.2015.65.0044","journal-title":"J Clin Oncol"},{"key":"9839_CR36","doi-asserted-by":"publisher","unstructured":"Lipman TO. Bacterial translocation and enteral nutrition in humans: an outsider looks in. JPEN J Parenter Enteral Nutr. 1995;19(2):156\u201365. https:\/\/doi.org\/10.1177\/0148607195019002156","DOI":"10.1177\/0148607195019002156"},{"issue":"14","key":"9839_CR37","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2004.04.132","volume":"22","author":"AB Benson","year":"2004","unstructured":"Benson AB, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA et al (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22(14):2918\u20132926. https:\/\/doi.org\/10.1200\/JCO.2004.04.132","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09839-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09839-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09839-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T02:56:52Z","timestamp":1758164212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09839-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["9839"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09839-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"8 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects (guidelines issued by the Japanese Government). This study approved by the ethics committees of the Japanese Red Cross Medical Center (reference number: 1443).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Information on this study was available on the webpage of the Japanese Red Cross Medical Center. Patients were notified about their participation in the study and informed that they were free to opt out.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"777"}}